touchOPHTHALMOLOGY touchOPHTHALMOLOGY
Macular Degeneration
Read Time: 2 mins

Foreword – European Ophthalmic Review, 2011;5(2):96

Copy Link
Published Online: Jan 24th 2012
Authors: Anat Loewenstein
Quick Links:
Article
Article Information
Article:

It is with great enthusiasm that I recommend to the readers this interesting issue of the European Ophthalmic Review for its wide-ranging coverage of hot topics and innovations in all subspecialities of ophthalmology. Each review stands for itself in being comprehensive and fascinating; nonetheless, the common denominators of the included papers are remarkable.


It is with great enthusiasm that I recommend to the readers this interesting issue of the European Ophthalmic Review for its wide-ranging coverage of hot topics and innovations in all subspecialities of ophthalmology. Each review stands for itself in being comprehensive and fascinating; nonetheless, the common denominators of the included papers are remarkable.
First, our endeavour to use safer methods of treatment and minimise incision size, thus intruding as little as possible into the normal eye structure, is manifested in the review on the treatment of diabetic macular oedema, beautifully illustrated by Francesco Bandello.
However, the concept that presents itself loud and clear from the majority of papers in the current issue is highlighting the importance of advanced imaging techniques for the way we diagnose, treat and follow up our patients. Using the ‘IOLMaster® 500 and Integration of the Holladay 2 Formula for Intraocular Lens Calculations’ is emphasising how we can improve our surgical results by using more sophisticated methods for imaging and measurements. The paper on intraocular pressure contact lenses also calls to attention how better diagnosis of the pressure status in a continuous manner can change the way we treat our patients.
‘Macular Pigment Density Measurement in Patients with Age-related Macular Degeneration’ may prove to be an important diagnostic and prognostic tool as demonstrated by Jens Dawczynski and colleagues.
In summary, this issue provides us with new data on techniques and imaging which are very likely to transform and modulate the way we treat our patients. â– 

Further Resources

Share this Article
Related Content In Macular Degeneration
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72